N- (2- (6- (4- cyclobutylamino- 5- trifluoromethylpyrimidine- 2- ylamino)- 1,2,3,4- tetrahydro- 1,4- epiazano- naphthalen- 9- yl)- 2- oxo- ethyl)acetamide

03/01/2012 - "The status of the Myc gene family and retinoblastoma pathway members significantly correlated with the efficacy of PF-03814735. "

03/01/2012 - "In vivo experiments with two SCLC xenograft models confirmed the sensitivity of Myc gene-driven models to PF-03814735 and a possible schedule dependence of MYC/c-Myc-driven tumors. "
04/01/2010 - "These results support the clinical evaluation of PF-03814735 in cancer patients. "
04/01/2010 - "Once-daily oral administration of PF-03814735 to mice bearing human xenograft tumors produces a reduction in phosphohistone H3 in tumors at doses that are tolerable and that result in significant inhibition of tumor growth. "
03/01/2012 - "To find predictive biomarkers of drug sensitivity, we screened a diverse panel of 87 cancer cell lines for growth inhibition upon PF-03814735 treatment. "
03/01/2012 - "PF-03814735 is a novel, reversible inhibitor of Aurora kinases A and B that finished a phase I clinical trial for the treatment of advanced solid tumors. "

03/01/2012 - "Small cell lung cancer (SCLC) and, to a lesser extent, colon cancer lines were very sensitive to PF-03814735. "

10/01/2019 - "Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor."

04/01/2010 - "PF-03814735 produces a block in cytokinesis, resulting in inhibition of cell proliferation and the formation of polyploid multinucleated cells. "